ClinicalTrials.gg
Enrolling by invitationNCT06830226DompMilkUpdated Mar 18, 2025

Domperidone on the Composition of Preterm Breastmilk Using a Human Milk Mid-infrared Spectroscopy Analyzer

An observational study in Insufficient Breast Milk Syndrome and Premature Birth, sponsored by Centro Hospitalar de Lisboa Central. Enrolling by invitation at 1 site in Portugal. Open to female participants. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Centro Hospitalar de Lisboa Central · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
81
Sex
Female
01

Study summary

Maintaining milk production in lactating mothers who have delivered prematurely can be a challenge. In these cases, domperidone has been the most commonly used pharmacologic galactagogue. There are several studies on the effect of this drug on the volume of milk produced, but data on its effect on the macronutrient and energy content is scarce. The mid-infrared spectroscopy is a convenient validated method to assess human milk macronutrient and energy content because it requires little training for its operation and a small volume of milk. This study aims to determine the effect of domperidone on the macronutrient and energy content of milk from women who have delivered prematurely, and to compare the results obtained with those reported using reference methods for this analysis.

Read the detailed description

Study design: This is a single-center observational study based on a convenience cohort of lactating women who have delivered before 37 weeks gestation.

Study period: A consecutive recruitment of participants will be scheduled over 12 months (from February 2, 2025), according to the availability of the observer (M.C.) in charge of the analysis of breast milk in the unit, performed weekly on a routine basis, in order to be fortified if necessary (Cardoso 2023).

Settings: Neonatal Intensive Care Unit (NICU) and Human Milk Bank at Maternidade Dr. Alfredo da Costa, Unidade Local de Saúde São José, Lisbon.

Product to be analyzed: breast milk Demographic variables: Retrieved demographic and clinical variables will include participant age and gestational age at delivery, reported body weight and height closer to the beginning of pregnancy, type of delivery (vaginal or cesarean), parity, pathological conditions during pregnancy (hypertension, pre-eclampsia, gestational diabetes, and intrauterine growth restriction), date of initiation of domperidone, whether it was prescribed by a health professional or on their own initiative, domperidone dosage, and days of lactation at the time of breast milk analyses.

Method of collection and analysis of breast milk: as described in previous studies (Macedo MHNP 2018, Cardoso 2021), mothers will be asked to save milk collected through 24 hours in the same container, in order to minimize daily variability of breast milk composition. The breast milk macronutrient and energy content will be analyzed using the Miris Human Milk analyzer (Miris AB, Uppsala, Sweden).

Measured breast milk macronutrient and energy content: The breast milk macronutrient and energy content will be analyzed using the Miris® Human Milk analyzer (Miris AB, Uppsala, Sweden) following the milk collection and analysis procedures described (Czosnykowska-Łukacka 2018, Macedo MHNP 2018, Cardoso 2021). Before each use, the analyzer will be calibrated using the standard calibration solution (Quan 2020). The breast milk composition will be expressed in densities: Kcal/dL of energy and g/dL of fat, total and true protein, carbohydrates, and ashes (Macedo MHNP 2018, Cardoso 2021).

According to the Unit's routine, the milk of mothers of preterm infants, particularly very preterm infants, is analyzed weekly to assess the need for fortification (Cardoso 2023).

Within-subject differences in the macronutrient and energy milk content will be determined by comparing the value of each parameter (total and true protein, total fat, total carbohydrates and energy) in the last measurement before starting domperidone (M0) with the respective value 14 days after starting (M14).

Estimate of sample size: The study sample size was calculated to detect an effect size of 0.35 between pairs of breastmilk content in total protein, with a significance level of 0.05, and an 80% power; thus, a required sample of 81 infants (67 participants more 20% for drop out) was estimated.

Statistical Analyses Mean of breastmilk macronutrient content will be compared by paired-t test for normal distributed differences or Wilcoxon test if non-normal distributed differences.

02

Conditions studied

  • Insufficient Breast Milk Syndrome
  • Premature Birth

Browse trials for

Keywords

  • breast milk
  • domperidone
  • energy
  • galactagogue
  • human milk analyzer
  • macronutrients
  • mid-infrared spectroscopy
  • premature birth
03

In context

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

This study's planned enrollment of 81 is below the median of 120 across 809 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Centro Hospitalar de Lisboa Central is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Lactating women who have delivered prematurely using domperidone as a galactagogue

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lactating women who have delivered prematurely using domperidone as a galactagogue, who will consent to participate, and who are not taking other substances or medications acting as galactagogues

Exclusion criteria

Exclusion Criteria:

  • Lactating women do not agree to participate
  • Lactating women use domperidone not as a galactagogue
  • Lactating women currently or previously taking other substances or medications acting as galactagogues
  • Lactating women taking medications that may alter the effect (such as ranitidine) or interact with domperidone (such as haloperidol)
  • Lactating women who have the diagnosis of mastitis
  • Lactating women with debilitating chronic illness
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
81 participants (estimated)
Target follow-up
14 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Test group

    Breast milk macronutrient and energy content assessed by mid-infrared spectroscopy method

    Dietary Supplement: Test group

  • Reference group

    Breast milk macronutrient and energy content assessed by Kjeldahl and Röse-Gottlib methods

    Dietary Supplement: Reference group

Interventions

  • Dietary supplementTest group

    In this group the Miris Human Milk analyzer will be used, consisting of a real-time mid-infrared technology that directly measures the concentration of protein, fat and carbohydrate, and calculates the energy content based on direct measurements.

  • Dietary supplementReference group

    In this group the Kjeldahl method will be used to assess total nitrogen concentration, the Röse-Gottlib method to assess fat concentration, and energy and carbohydrate concentration will be calculated by differences. Kjeldahl and the Röse-Gottlib are considered reference methods

06

What researchers measure

Primary outcomes

  1. True protein content

    Within-subject difference of breastmilk content in true protein (protein with nutritional value)

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

Secondary outcomes

  1. Total protein

    Within-subject difference of breastmilk content in total protein

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  2. Fat

    Within-subject difference of breastmilk content in fat

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  3. Carbohydrate

    Within-subject difference of breastmilk content in carbohydrate

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  4. Total energy content

    Within-subject difference of breastmilk content in total energy

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  5. Percentage differences for total protein

    The mean of the percentage differences for total protein obtained in the test group will be compared with the correspondent value obtained in the reference group.

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  6. Percentage differences for true protein

    7The mean of the percentage differences for true protein obtained in the test group will be compared with the correspondent value obtained in the reference group

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  7. Percentage differences for fat

    The mean of the percentage differences for fat obtained in the test group will be compared with the correspondent value obtained in the reference group

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  8. Percentage differences for carbohydrate

    The mean of the percentage differences for carbohydrate obtained in the test group will be compared with the correspondent value obtained in the reference group

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

  9. Percentage differences for total energy

    The mean of the percentage differences for total energy obtained in the test group will be compared with the correspondent value obtained in the reference group

    Time frame: Between the last assessment before starting domperidone and the assessment 14 days after starting domperidone. The difference value between 14 days after domperidone and before starting it, expressed as percentage of the value before starting domperidone

07

Study locations

1 site
08

References and documents

Publications

  • Czosnykowska-Lukacka M, Krolak-Olejnik B, Orczyk-Pawilowicz M. Breast Milk Macronutrient Components in Prolonged Lactation. Nutrients. 2018 Dec 3;10(12):1893. doi: 10.3390/nu10121893. PubMed 30513944 ↗
  • Cardoso M, Virella D, Papoila AL, Alves M, Macedo I, E Silva D, Pereira-da-Silva L. Individualized Fortification Based on Measured Macronutrient Content of Human Milk Improves Growth and Body Composition in Infants Born Less than 33 Weeks: A Mixed-Cohort Study. Nutrients. 2023 Mar 22;15(6):1533. doi: 10.3390/nu15061533. PubMed 36986263 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2025, 6 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 6 months is below that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Jan 8, 2025
Primary completionEst.
Jul 30, 2025
CompletionEst.
Aug 30, 2025
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830226
Lead sponsor
Centro Hospitalar de Lisboa Central
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Jan 8, 2025
Primary completion
Jul 30, 2025 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Mar 18, 2025

Study contacts

Daniel Virella, MD, MSc
study chair · Unidade Local de Saúde São José

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion